1. Market Research
  2. > Pharmaceutical
  3. > Therapy Market Trends
  4. > Global Rising Stars Outlook 2015: Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets.

Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets , approaches and biology is discovered. One field which is poised to bring a paradigm change in the way diseases are treated in the next decades is the Stem cell therapy/Regenerative Medicine space. The number of companies and products in the clinic have reached a critical mass warranting a close watch for those interested in keeping pace with the development of new medicines. The Regenerative medicine Universe is large and new companies are being added to it rapidly. As a result we have used some filters to select a few names for a detailed coverage in our Outlook this year.

Key Criteria for Our Selection are:
- Uniqueness of the Technology platform and the ability to scale up commercially in case of positive outcome of products in the pipeline
- Pipeline and clinical data analysis
- Marketed product and commercial tie up. Robustness of the Management, financial and business model.

Table Of Contents

Global Rising Stars Outlook 2015: Innovative Therapies for treating diseases are being sought after with fresh vigor as new targets.
Part 1- Rising Stars in Regenerative Medicine and Stem cell based Cell Therapies-Drugs of the Future

Company Analysis:
CESCA Therapeutics Inc. : Hedging the Risk with Stem Cell Based Devices and Therapies and Global Presence
- Figure 1: Products In Pipeline
- Table 1: Clinical Development- Critical Limb Ischemia (ClI)Data Key Milestones
Ocata Therapeutics Inc: Ophthalmic Focus- Macular degenerative conditions- Looking with a New Eye
- Figure 1: Market For Age-Related Macular Degeneration (AMD)
- Figure 2: Products In The Pipeline
Orgenesis: Focus- Diabetes- Tricking your Liver to Make Insulin!
- Technology Platform
- Figure 1: Schematic Representation Of Making Autologous Insulin Producing (AIP) Cell
Tigenix NV : Exploiting the Adipose Tissue- Multiple Applications of Fat?
- Technology Platform
- Marketed Products
- Figure 1 : Products In Pipeline
- Key Milestones
Pluristem Therapeutics Inc: Regenerating and Recycling- Allogenic Therapies from the Placenta
- PluriX 3D Technology Platform
- Pipeline
- Figure 1 : Classification Of Peripheral Arterial Disease Types
- Market Opportunity
- Key Milestones
Mesoblast: Leader in Regenerative Sapce in Korea- Focusing on International Markets
- Technology Platform
- Pipeline- Focus on four major areas
- Figure 1: Drugs In The Pipeline
- Figure 2 : CHFf Discease Classification And Target Patients In PhIII Trial
- Figure 3: PhiII Data Of MPC-150 In CHF
- Figure 4 : Market Opportunity In Chronic Low Back Pain (CLBP)
- Key Milestones
Medipost Co Ltd : Leader in Regenerative Space in Korea- Focusing on International Markets
- Marketed and Products in the Pipeline
- Key Milestones
- Figure 1: Sales By Business Segment

JCR Pharmaceuticals co. Ltd.: First Stem Cell Based Product in Japan for Graft-Versus-Host Disease (GVHD).
- Technology Platform
- Product in the Pipeline
- Key Milestones
- Facts and Financials
- Table 1 : Pipeline Table
- Figure 1: Sales By Business Segments
Japan Tissue Engineering co. Ltd: Building Confidence in Regenerative Medicine- Fuji film Venture from Colors to Regenerative Medicine-
- Plat form Focus
- Products
- Figure 1 : Therapy and Product Focus


Part II-Indian Innovators- Rising Stars:
- Table 1: Select new generation innovation /drug discovery Indian companies
Connexios: Maturing Pipeline and Focus on Diabetes/Metabolic Disorders to Drive Visibility
- Technology Platform
- Therapy Focus—Diabetes/Metabolic Disorder and Non Alcoholic Steatohepatitis (NASH)
- Key Milestones
- Table 1: Differences Between G-Protein Coupled Receptor Agonists
- Table 2: Pipeline Of GPR Agonist For Treatment Of Type 2 Diabetes
- Figure 1: Products In Pipeline- Diabetes
- Figure 2: Products In Pipeline For NASH
- Figure 3: Other Programs
Cellworks : In silico Technology Platform Poised to Deliver- Focus on Personalised Medicine and Cancer
- Figure 1 : Simulation Based Personalized Medicine
- Figure 2 : Cellworks Therapeutic Programs
Bugworks: In silico Technology platform being applied to Serious Hospital Infections- Need of the hour!
- Therapy focus- Serious Hospital Infection
- Technology Platform
- Figure 1: Drug Development Success For TB
- Figure 2 : Going Way Froward
Tergene : Affordable and Second Generation Vaccines- Addressing the Urgent needs of Emerging Markets.
- Development Strategy and Status
- Figure 1: Sales Of Currently Available Vaccines For Streptococcus Pneumonia
- Figure 2: WW Demand Forecast Of Vaccines For Streptococcus Pneumonia
- Figure 3: Vaccine Market

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Veronica

+1 718 514 2762

Purchase Reports From Reputable Market Research Publishers
PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025

  • $ 10995
  • Industry report
  • October 2016
  • by Global Data

PharmaPoint: Major Depressive Disorder - Global Drug Forecast and Market Assessment to 2025 Summary Major depressive disorder (MDD) is one of the most common psychiatric diseases worldwide. It is characterized ...

Colorectal Cancer KOL Insight 2016

Colorectal Cancer KOL Insight 2016

  • $ 8085
  • Industry report
  • October 2016
  • by Firstword Pharma

KOLs embrace novel MoAs as low survival rates drive search for new treatments Faced with persistently low survival rates, KOLs are calling for new approaches to treat late-stage colorectal cancer (CRC). ...

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations

  • $ 6995
  • Industry report
  • December 2016
  • by GBI Research

Frontier Pharma: Hepatitis C - Diverse Range of First-in-Class Host-Targeting and Direct-Acting Antivirals Offer Potential in Difficult-to-Treat Populations Summary Hepatitis C is a blood-borne viral infection ...


Download Unlimited Documents from Trusted Public Sources

Biological Therapy Industry in the US

  • January 2017
    9 pages
  • Vaccine  

  • United States  

View report >

Therapy Market in the UK

  • January 2017
    19 pages
  • Therapy  

  • United Kingdom  

View report >

Global Therapy Market

  • January 2017
    32 pages
  • Therapy  

    Targeted Therap...  

    Monoclonal Anti...  

  • World  

View report >

Related Market Segments :

Therapy

ref:plp2015

Reportlinker.com © Copyright 2017. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.